RU2003138127A -
METHOD FOR ESTIMATING EFFECTIVENESS OF TREATMENT OF CRITICAL ISCHEMIA OF LOWER EXTREMITIES
- Google Patents
METHOD FOR ESTIMATING EFFECTIVENESS OF TREATMENT OF CRITICAL ISCHEMIA OF LOWER EXTREMITIES
Download PDF
Info
Publication number
RU2003138127A
RU2003138127ARU2003138127/14ARU2003138127ARU2003138127ARU 2003138127 ARU2003138127 ARU 2003138127ARU 2003138127/14 ARU2003138127/14 ARU 2003138127/14ARU 2003138127 ARU2003138127 ARU 2003138127ARU 2003138127 ARU2003138127 ARU 2003138127A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виктор Анатольевич Лазаренко (RU), Виктор Анатольевич Лазаренко, Роман Николаевич Терещенко (RU), Роман Николаевич ТерещенкоfiledCriticalВиктор Анатольевич Лазаренко (RU)
Priority to RU2003138127/14ApriorityCriticalpatent/RU2257141C1/en
Publication of RU2003138127ApublicationCriticalpatent/RU2003138127A/en
Application grantedgrantedCritical
Publication of RU2257141C1publicationCriticalpatent/RU2257141C1/en
Measuring And Recording Apparatus For Diagnosis
(AREA)
Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body
(AREA)
Claims (1)
Способ оценки эффективности лечения критической ишемии нижних конечностей, отличающийся тем, что используют оригинальную шкалу изменений в клинико-инструментальном статусе пациентов с критической ишемией нижних конечностей до и после проведенного консервативного лечения.A method for evaluating the effectiveness of treatment of critical lower limb ischemia, characterized in that the original scale of changes in the clinical and instrumental status of patients with critical lower limb ischemia is used before and after conservative treatment.
RU2003138127/14A2003-12-302003-12-30Method for evaluating efficiency in treating critical ischemia of inferior limbs
RU2257141C1
(en)
New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease